Preclinical evaluation of [58mCo]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer

Preclinical evaluation of [58mCo]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer

Abstract Prostate-specific membrane antigen (PSMA), highly expressed in prostate cancer, is a promising target for radionuclide therapy. Auger electron-emitting radionuclides are well suited for targeted radionuclide therapy if they can be delivered close to the DNA of the targeted cells. This precl...

Full description

Bibliographic Details
Main Authors: Christina Baun, Johan Hygum Dam, Malene Grubbe Hildebrandt, Jesper Dupont Ewald, Bjarne Winther Kristensen, Vigga Sand Gammelsrød, Birgitte Brinkmann Olsen, Helge Thisgaard
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-43429-8

Internet

https://doi.org/10.1038/s41598-023-43429-8

Similar Items